Central Nervous System Prophylaxis in Non-Hodgkin Lymphoma: Who, What, and When?

1.

Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002;13(7):1099–107.CrossRefPubMed

2.

Ferreri AJM, Assanelli A, Crocchiolo R, Ciceri F. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematol Oncol. 2009;27(2):61–70. doi:10.1002/hon.881.CrossRefPubMed

3.

Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muniz C, et al. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2014;99(7):1228–35. doi:10.3324/haematol.2013.101741.CrossRefPubMedCentralPubMed

4.

Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007;18(3):541–5. doi:10.1093/annonc/mdl434.CrossRefPubMed

5.

Aviles A, Jesus Nambo M, Neri N. Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center. Med Oncol. 2013;30(2):520. doi:10.1007/s12032-013-0520-0.CrossRefPubMed

6.

Mitrovic Z, Bast M, Bierman PJ, Bociek RG, Vose JM, Chan WC, et al. The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. Br J Haematol. 2012;157(3):401–3. doi:10.1111/j.1365-2141.2011.08998.x.CrossRefPubMed

7.

Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol. 2011;90(7):809–18. doi:10.1007/s00277-010-1150-7.CrossRefPubMed

8.

Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2012;103(2):245–51. doi:10.1111/j.1349-7006.2011.02139.x.CrossRefPubMed

9.

Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21(5):1046–52. doi:10.1093/annonc/mdp432.CrossRefPubMed

10.

van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91(4):1178–84.PubMed

11.

Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma. 2011;52(12):2270–5. doi:10.3109/10428194.2011.596966.CrossRefPubMed

12.

Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol. 2009;89(5):577–83. doi:10.1007/s12185-009-0289-2.CrossRefPubMed

13.

Yamamoto W, Tomita N, Watanabe R, Hattori Y, Nakajima Y, Hyo R, et al. Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol. 2010;85(1):6–10. doi:10.1111/j.1600-0609.2010.01438.x.PubMed

14.

Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896–902. doi:10.1182/blood-2008-10-182253.CrossRefPubMed

15.

Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15(1):129–33.CrossRefPubMed

16.

Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2013. doi:10.3109/10428194.2013.811239.

17.

Nitta H, Terui Y, Yokoyama M, Mishima Y, Nishimura N, Ueda K, et al. Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma. Haematologica. 2015;100(1):87–90. doi:10.3324/haematol.2014.114934.CrossRefPubMedCentralPubMed

18.••

Schmitz N, Zeynalova S, Nickelsen M, Ziepert M, Pfreundschuh M, Glass B, et al. A new prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Hematol Oncol. 2013;31(S1):96–150. doi:10.1002/hon.2057. Abstract proposing the DSHNHL CNS prediction model.CrossRef

19.••

Savage KJ, Zeynalova S, Kansara RR, Nickelsen M, Villa D, Sehn LH, et al. Validation of a prognostic model to assess the risk of cns disease in patients with aggressive B-cell lymphoma. Blood (ASH Ann Meet Abstr). 2014;124(21):394. Validation of the DSHNHL CNS predicition model in an independent, uniformly treated cohort.

20.

Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014;123(4):486–93. doi:10.1182/blood-2013-10-530659.CrossRefPubMed

21.

Sagoo MS, Mehta H, Swampillai AJ, Cohen VM, Amin SZ, Plowman PN, et al. Primary intraocular lymphoma. Surv Ophthalmol. 2014;59(5):503–16. doi:10.1016/j.survophthal.2013.12.001.CrossRefPubMed

22.

Kim MM, Dabaja BS, Medeiros J, Kim S, Allen P, Chevez-Barrios P, et al. Survival outcomes of primary intraocular lymphoma: a single-institution experience. Am J Clin Oncol. 2014. doi:10.1097/coc.0000000000000028.

23.

Grigg AP, Connors JM. Primary adrenal lymphoma. Clin Lymphoma. 2003;4(3):154–60.CrossRefPubMed

24.

Hu R, Zhang R, Miao M, Zhu K, Yang W, Liu Z. Central nervous system involvement of primary renal lymphoma with diffuse large B-cell type lymphoma. Am J Case Rep. 2013;14:292–4. doi:10.12659/ajcr.889308.CrossRefPubMedCentralPubMed

25.

Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev. 2006;20(6):319–32. doi:10.1016/j.blre.2006.02.001.CrossRefPubMed

26.

Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol. 1990;8(3):141–5.CrossRefPubMed

27.

Jacobs C, Hoppe RT. Non-Hodgkin's lymphomas of head and neck extranodal sites. Int J Radiat Oncol Biol Phys. 1985;11(2):357–64.CrossRefPubMed

28.

Mian M, Capello D, Ventre MB, Grazio D, Svaldi M, Rossi A, et al. Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study). Ann Hematol. 2013. doi:10.1007/s00277-013-1856-4.

29.

Di Marco A, Campostrini F, Garusi GF. Non-Hodgkin lymphomas presenting with spinal epidural involvement. Acta Oncol. 1989;28(4):485–8.CrossRefPubMed

30.

Eeles RA, O'Brien P, Horwich A, Brada M. Non-Hodgkin's lymphoma presenting with extradural spinal cord compression: functional outcome and survival. Br J Cancer. 1991;63(1):126–9.CrossRefPubMedCentralPubMed

31.

McDonald AC, Nicoll JA, Rampling RP. Non-Hodgkin's lymphoma presenting with spinal cord compression: a clinicopathological review of 25 cases. Eur J Cancer. 2000;36(2):207–13.CrossRefPubMed

32.

Salvati M, Cervoni L, Artico M, Raco A, Ciappetta P, Delfini R. Primary spinal epidural non-Hodgkin's lymphomas: a clinical study. Surg Neurol. 1996;46(4):339–43. discussion 43-4.CrossRefPubMed

33.

Perry JR, Deodhare SS, Bilbao JM, Murray D, Muller P. The significance of spinal cord compression as the initial manifestation of lymphoma. Neurosurgery. 1993;32(2):157–62.CrossRefPubMed

34.

Lyons MK, O'Neill BP, Marsh WR, Kurtin PJ. Primary spinal epidural non-Hodgkin's lymphoma: report of eight patients and review of the literature. Neurosurgery. 1992;30(5):675–80.CrossRefPubMed

35.

Epelbaum R, Haim N, Ben-Shahar M, Ben-Arie Y, Feinsod M, Cohen Y. Non-Hodgkin's lymphoma presenting with spinal epidural involvement. Cancer. 1986;58(9):2120–4.CrossRefPubMed

36.

Rathmell AJ, Gospodarowicz MK, Sutcliffe SB, Clark RM. Localized extradural lymphoma: survival, relapse pattern and functional outcome. The Princess Margaret Hospital Lymphoma Group. Radiother Oncol. 1992;24(1):14–20.CrossRefPubMed

37.

Monnard V, Sun A, Epelbaum R, Poortmans P, Miller RC, Verschueren T, et al. Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2006;65(3):817–23. doi:10.1016/j.ijrobp.2006.01.002.CrossRefPubMed

38.

Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol. 2006;76(6):473–80. doi:10.1111/j.1600-0609.2006.00644.x.CrossRefPubMed

39.

Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol. 1998;9(2):191–4.CrossRefPubMed

40.

Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma. Cancer. 2002;95(3):576–80. doi:10.1002/cncr.10699.CrossRefPubMed

41.

Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2013;55(3):509–14. doi:10.3109/10428194.2013.811239.CrossRefPubMed

42.

Gleeson M, Cunningham D, Hawkes EA, Qian W, Smith P, Chadwick N, et al. Risk of CNS relapse with diffuse large B-cell lymphoma (DLBCL) in the rituximab era: results from the UK NCRI R-CHOP 14 v 21 Trial. Blood (ASH Ann Meet Abstr). 2014;124(21):1723.

43.

Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012;118(11):2944–51. doi:10.1002/cncr.26588.CrossRefPubMed

44.

Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20–7.CrossRefPubMed

45.

Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29(20):2766–72. doi:10.1200/jco.2010.31.4187.CrossRefPubMed

46.

Yun J, Kim SJ, Won JH, Choi CW, Eom HS, Kim JS, et al. Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: a Consortium for Improving Survival of Lymphoma (CISL) report. Leuk Res. 2010;34(9):1175–9. doi:10.1016/j.leukres.2010.02.010.CrossRefPubMed

47.

Aviv A, Tadmor T, Polliack A. Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol. 2013;24(9):2236–44. doi:10.1093/annonc/mdt192.CrossRefPubMed

48.

Guo H-Y, Zhao X-M, Li J, Hu X-C. Primary non-Hodgkin’s lymphoma of the breast: eight-year follow-up experience. Int J Hematol. 2008;87(5):491–7. doi:10.1007/s12185-008-0085-4.CrossRefPubMed

49.

Fukuhara S, Watanabe T, Munakata W, Mori M, Maruyama D, Kim SW, et al. Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution. Eur J Haematol. 2011;87(5):434–40. doi:10.1111/j.1600-0609.2011.01679.x.CrossRefPubMed

50.

Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose JM, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014. doi:10.1111/bjh.12753.PubMedCentral

51.

Papageorgiou SG, Diamantopoulos P, Levidou G, Angelopoulou MK, Economopoulou P, Efthimiou A, et al. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. Hematol Oncol. 2013;31(1):10–7. doi:10.1002/hon.2012.CrossRefPubMed

52.

Bekkenk MW, Postma TJ, Meijer CJ, Willemze R. Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma. Cancer. 2000;89(4):913–9.CrossRefPubMed

53.

Ponzoni M, Ferreri AJ, Campo E, Facchetti F, Mazzucchelli L, Yoshino T, et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol: Off J Am Soci Clin Oncol. 2007;25(21):3168–73. doi:10.1200/JCO.2006.08.2313.CrossRef

54.

Shimada K, Murase T, Matsue K, Okamoto M, Ichikawa N, Tsukamoto N, et al. Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci. 2010;101(6):1480–6. doi:10.1111/j.1349-7006.2010.01555.x.CrossRefPubMed

55.

Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol. 2004;127(2):173–83. doi:10.1111/j.1365-2141.2004.05177.x.CrossRefPubMed

56.

Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, et al. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncol. 2008;26(31):5134–6.CrossRefPubMed

57.

Ferreri AJ, Campo E, Ambrosetti A, Ilariucci F, Seymour JF, Willemze R, et al. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol. 2004;15(8):1215–21. doi:10.1093/annonc/mdh274.CrossRefPubMed

58.

Cheah CY, Oki Y, Westin JR, Turturro F. A clinician's guide to double hit lymphomas. Br J Haematol. 2014. doi:10.1111/bjh.13276.PubMed

59.

Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–9. doi:10.1200/JCO.2011.41.0985.CrossRefPubMedCentralPubMed

60.

Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3):327–40. doi:10.1097/PAS.0b013e3181cd3aeb.CrossRefPubMedCentralPubMed

61.

Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92(10):1335–42. doi:10.3324/haematol.11305.CrossRefPubMed

62.

Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19(1):25–33. doi:10.1038/modpathol.3800500.CrossRefPubMed

63.

Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891–901. doi:10.1111/bjh.12982.CrossRefPubMed

64.

Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–61. doi:10.1182/blood-2014-05-578963.CrossRefPubMed

65.

Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460–7. doi:10.1200/jco.2011.41.4342.CrossRefPubMed

66.

Savage KJ, Sehn LH, Villa D, Kansara RR, Mottok A, Ennishi D, et al. The impact of concurrent MYC BCL2 protein expression on the risk of secondary central nervous system relapse in diffuse large B-cell lymphoma (DLBCL). Blood (ASH Ann Meet Abstr). 2014;124(21):495.

67.

Lowenthal DA, Straus DJ, Campbell SW, Gold JWM, Clarkson BD, Koziner B. AIDS-related lymphoid neoplasia. The memorial hospital experience. Cancer. 1988;61(11):2325–37. doi:10.1002/1097-0142(19880601)61:11<2325::AID-CNCR2820611130>3.0.CO;2-0.CrossRefPubMed

68.

Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. New Eng J Med. 1997;336(23):1641–8. doi:10.1056/NEJM199706053362304.CrossRefPubMed

69.

Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538–43. doi:10.1182/blood-2005-04-1437.CrossRefPubMedCentralPubMed

70.

Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105(5):1891–7. doi:10.1182/blood-2004-08-3300.CrossRefPubMed

71.

Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354(23):2431–42. doi:10.1056/NEJMoa055759.CrossRefPubMed

72.

Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol. 2003;4(1):22–9.CrossRefPubMed

73.

Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319–31. doi:10.1182/blood-2010-09-297879.CrossRefPubMed

74.

Boulanger E, Gérard L, Gabarre J, Molina J-M, Rapp C, Abino J-F, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005;23(19):4372–80. doi:10.1200/jco.2005.07.084.CrossRefPubMed

75.

Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol. 2003;21(21):3948–54. doi:10.1200/jco.2003.06.013.CrossRefPubMed

76.

Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, et al. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011;35(12):1571–7.CrossRefPubMed

77.

Ustun C, Reid-Nicholson M, Nayak-Kapoor A, Jones-Crawford J, McDonald K, Jillella AP, et al. Plasmablastic lymphoma: CNS involvement, coexistence of other malignancies, possible viral etiology, and dismal outcome. Ann Hematol. 2009;88(4):351–8. doi:10.1007/s00277-008-0601-x.CrossRefPubMed

78.

Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51(11):2047–53. doi:10.3109/10428194.2010.516040.CrossRefPubMed

79.

Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012;119(14):3245–55. doi:10.1182/blood-2011-08-373738.CrossRefPubMedCentralPubMed

80.

Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15(4):1587–94.PubMed

81.

Ghesquieres H, Berger F, Felman P, Callet-Bauchu E, Bryon PA, Traverse-Glehen A, et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol. 2006;24(33):5234–41. doi:10.1200/JCO.2006.07.5671.CrossRefPubMed

82.

Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22(7):1601–7. doi:10.1093/annonc/mdq627.CrossRefPubMed

83.

Cheah CY, George A, Giné E, Chiappella A, Kluin-Nelemans HC, Jurczak W, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol. 2013. doi:10.1093/annonc/mdt139.PubMed

84.

Conconi A, Franceschetti S, Lobetti-Bodoni C, Stathis A, Bruna R, Riccomagno P, et al. Central nervous system (CNS) relapse in a population of 143 patients (Pts) with mantle cell lymphoma (MCL) from two centers. ASH Ann Meet Abstr. 2011;118(21):2660.

85.

Gill S, Herbert KE, Prince HM, Wolf MM, Wirth A, Ryan G, et al. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol. 2009;147(1):83–8. doi:10.1111/j.1365-2141.2009.07835.x.CrossRefPubMed

86.

Oinonen R, Franssila K, Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol. 1999;78(3):145–9.CrossRefPubMed

87.

Valdez R, Kroft SH, Ross CW, Schnitzer B, Singleton TP, Peterson LC, et al. Cerebrospinal fluid involvement in mantle cell lymphoma. Mod Pathol. 2002;15(10):1073–9. doi:10.1097/01.MP.0000030088.28684.5B.CrossRefPubMed

88.

Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015. doi:10.1093/annonc/mdv111

89.

Ellin F, Landström J, Jerkeman M, Relander T. Patterns of central nervous system relapse in peripheral T-cell lymphomas—population-based data from the Swedish Lymphoma Registry. vol 21. 2014.

90.

Yi JH, Kim JH, Baek KK, Lim T, Lee DJ, Ahn YC, et al. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma. Ann Oncol. 2011;22(7):1636–43. doi:10.1093/annonc/mdq645.CrossRefPubMedCentralPubMed

91.

Kim SJ, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol. 2010;21(5):1058–63. doi:10.1093/annonc/mdp412.CrossRefPubMed

92.

Stein M, Farrar N, Jones GW, Wilson LD, Fox L, Wong RK, et al. Central neurologic involvement in mycosis fungoides: ten cases, actuarial risk assessment, and predictive factors. Cancer J. 2006;12(1):55–62.CrossRefPubMed

93.

Vergier B, de Muret A, Beylot-Barry M, Vaillant L, Ekouevi D, Chene G, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood. 2000;95(7):2212–8.PubMed

94.

Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516—the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114–9. doi:10.1200/JCO.2008.16.8021.CrossRefPubMed

95.

Cheah CY, Seymour JF, Dickinson M. Ongoing challenge of optimal patient selection for CNS prophylaxis in patients with non-Hodgkin lymphoma. Int J Hematol Oncol. 2014;3(3):189–201. doi:10.2217/ijh.14.15.

96.

Chua SL, Seymour JF, Streater J, Wolf MM, Januszewicz EH, Prince HM. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2002;43(9):1783–8. doi:10.1080/1042819021000006475.CrossRefPubMed

97.

Grossman SA, Reinhard CS, Loats HL. The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study. J Neurooncol. 1989;7(4):319–28. doi:10.1007/BF02147089.CrossRefPubMed

98.

Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102(13):4284–9. doi:10.1182/blood-2003-02-0542.CrossRefPubMed

99.

Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116(18):4283–90. doi:10.1002/cncr.25278.CrossRefPubMed

100.

Holte H, Leppä S, Björkholm M, Fluge Ø, Jyrkkiö S, Delabie J, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013;24(5):1385–92. doi:10.1093/annonc/mds621.CrossRefPubMed

101.••

Cheah CY, Herbert KE, O'Rourke K, Kennedy GA, George A, Fedele PL, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014;111(6):1072–9. doi:10.1038/bjc.2014.405. One of two retrospective controlled studies in patients treated with rituximab and chemotherapy showing that the addition of high-dose systemic methotrexate reduces CNS relapse.CrossRefPubMed

102.••

Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol. 2014. doi:10.1111/bjh.13194. One of two retrospective controlled studies in patients treated with rituximab and chemotherapy showing that the addition of high-dose systemic methotrexate reduces CNS relapse.

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Central Nervous System Prophylaxis in Non-Hodgkin Lymphoma: Who, What, and When?

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

Rethinking Clinical Response and Outcome Assessment in a Biologic Age

Tivozanib: Status of Development

Ultrasound in Gynecological Cancer: Is It Time for Re-evaluation of Its Uses?

The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update

Keynote webinar | Spotlight on antibody–drug conjugates in cancer